Keverprazan hydrochloride - Jiangsu Carephar pharmaceuticals
Alternative Names: Bei Wen; Carenoprazan hydrochloride - Jiangsu Carephar Pharmaceutical; H-008; KFP-H008Latest Information Update: 28 Jul 2024
At a glance
- Originator Jiangsu Carephar Pharmaceutical
- Class Anti-inflammatories; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Duodenal ulcer; Gastro-oesophageal reflux
- No development reported Erosive oesophagitis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Erosive-oesophagitis(In volunteers) in USA (PO, Tablet)
- 08 Mar 2023 Efficacy and adverse events data from a phase III trial in Gastro-oesophageal-reflux released by Jiangsu Carephar Pharmaceutical
- 15 Feb 2023 First global approval - Registered for Duodenal ulcer in China (PO)